Lumiliximab, also known as ST-152, represents a promising monoclonal targeting the soluble receptor for interleukin -13. The agent demonstrates impressive potential in managing scarring diseases , particularly those involving cardiac dysfunction. Studies indicate that the antibody effectively inh

Satralizumab, previously known as compound SA-237 , represents a exciting treatment for a form of multiple sclerosis and other inflammatory conditions . Recent clinical trials have shown positive data regarding its effectiveness in lessening relapses and condition progression . In particular , P

Emerging data suggests that Cilgavimab, formerly known as COV2-2130, holds significant capability as a medicinal agent in combating COVID-19. This immunoglobulin exhibits a novel mechanism of action , specifically targeting the pathogen's ACE2-RBD with exceptional binding power. Early studies sho